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Background: In this investigation, the antileukemic activity of a new nanomedicine based on 
the conjugation of 1,1′,2-tris-nor-squalenic acid with cytarabine (Ara-C) was evaluated.
Methods: Squalenoyl-Ara-C conjugate (Sq-Ara-C) self-assembled nanosystems were obtained 
by the nanoprecipitation method and characterized in vitro and in vivo.
Results: This new nanomedicine, which had a mean diameter of approximately 150 nm, 
improved the in vitro antitumoral activity of Ara-C in different cancer cell lines (L1210, K562, 
and MCF-7). Sq-Ara-C nanomedicine allowed reduction of the IC
50
 value with respect to the free 
drug and was also active against drug-resistant leukemic cells (L1210R). A noticeable increase 
in the survival rate of mice with aggressive metastatic L1210R leukemia was observed after 
treatment with Sq-Ara-C (50 mg/kg) as compared with the free active compound (100 mg/kg). 
Finally, evaluation of the biodistribution and pharmacokinetic profiles of the drug demonstrated 
that these nanoaggregates preferentially localized to the liver and spleen, and protected the drug 
from physiological metabolism.
Conclusion: Squalenoylation of cytarabine offers several pharmacological benefits both 
in vitro and in vivo.
Keywords: squalenoyl-cytarabine, self-assembly, antitumoral nanomedicine, leukemia, 
 nanoaggregate, biodistribution
Introduction
Acute myeloid leukemia is a heterogeneous group of diseases characterized by 
uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells and 
impaired production of normal hematopoiesis, leading to neutropenia, anemia, and 
 thrombocytopenia.1 1-β-D-arabinofuranosylcytosine (cytarabine, Ara-C) is standard 
therapy for acute and post-remission myeloid leukemia, especially in association with 
other active compounds, such as anthracyclines and etoposide.2,3
Inside the cell, Ara-C is metabolized via the pathways normally utilized by natural 
nucleotide precursors. The metabolic step which limits the activation of Ara-C is its 
phosphorylation into Ara-CMP, which is carried out by deoxycytidine kinases. Ara-CMP 
is then activated by the pyrimidine, nucleoside monophosphate, and diphosphate kinases 
into Ara-CDP and Ara-CTP, respectively. Rapid deamination of Ara-C by cytidine deami-
nase catabolizes it into the nontoxic metabolite, Ara-U (1-β-D-arabinofuranosyluracil).4 
Unfortunately, several mechanisms of cellular drug resistance have been described in 
patients with acute myeloid leukemia, in particular, the presence of transmembranic 
efflux pumps, such as P-glycoprotein, the difficulty of obtaining the triphosphorylated 
form of the drug inside cells, and deregulation of specific membrane nucleoside 
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 transporters (hENT1). All of these factors seem to influence 
the pharmacological efficacy of the active compound.5,6 Ara-C 
is also metabolized extracellularly by cytidine deaminase, 
leading to a short plasma half-life of 1.5 hours.7
To overcome these limitations, a possible strategy could 
be drug encapsulation within a colloidal device in order to 
avoid destabilization phenomena.8–10 Our research team has 
used gemcitabine as a model compound with the aim of 
demonstrating the efficacy of liposomal and supramolecular 
carriers as drug delivery systems, showing improvement in the 
biopharmaceutical properties of the encapsulated molecules 
when compared with their free couterparts.11,12 Moreover, lipo-
somal cytarabine (Depocyte®) is also being used increasingly 
for the treatment and prophylaxis of central nervous system 
involvement in patients with leukemia/lymphoma.13–15
A new approach to improving the biopharmaceutical 
properties of the nucleoside analogs is their conjugation 
with the acyclic isoprenoid chain of squalene, a precursor 
in the biosynthesis of sterol. Squalene is widely distributed 
throughout nature, and is found particularly in olives, shark 
liver oil, wheat germ, and rice bran; it is also distributed 
ubiquitously in human tissues, particularly in the skin, and 
is well tolerated following intravenous injection and oral 
administration.16 It is very interesting to note that squalene 
inhibits proliferation of cancer cells by decreasing farnesyl 
pyrophosphate levels and does not influence normal bio-
chemical pathways.17,18
The squalenoylation of some bioactive compounds allows 
nanostructures to self-assemble in an aqueous environment; 
these nanostructures are characterized by a hexagonal con-
formation in which the drug compound is surrounded by a 
shell.19 It has been observed that these nanoaggregates tend 
to improve the biopharmaceutical properties of compounds 
linked to squalenic acid, thus improving their antitumoral 
effects, prolonging the half-lives of antineoplastic drugs, and 
enhancing their interaction with biomembranes.20–23
In this investigation, a novel squalenoyl-Ara-C conjugate 
(Sq-Ara-C) was synthesized and prepared in the form of a 
nanomedicine, which was compared in vitro with the native 
drug in different cancer cell lines to confirm antitumoral 
activity. The Sq-Ara-C nanomedicine was also investigated 
in vivo with regard to its pharmacokinetic, biodistribution, 
and antileukemic characteristics in a mouse model.
Materials and methods
Materials
Cytarabine (1-β-D-arabinofuranosylcytosine, Ara-C, 
purity .99%), dextrose, N-(fluorescein-5-tiocarbamoyl)-
1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine 
triethylammonium salt (fluorescein-DHPE), phosphate-
buffered saline solution, 3-[4,5-dimethylthiazol-2-yl]-
3,5-diphenyltetrazolium bromide salt (used for MTT 
testing), dimethylsulfoxide and amphotericin B solution 
(250 µg/mL) were purchased from Sigma-Aldrich (Milan, 
Italy). Squalene (purity .99%) was purchased from VWR 
(Milan, Italy). 1,1′,2-tris-nor-squalene aldehyde was obtained 
from squalene using a method described previously.24 
[3H]cholesteryl hexadecyl ether ([3H]CHE, 40 Ci/mmoL) 
was obtained from Perkin Elmer-Italia (Monza, Italy). 
L1210 cells, K562 cells, and MCF-7 cells were provided by 
the Istituto Zooprofilattico of Modena and Reggio Emilia. 
RPMI 1640 medium with GlutaMAX™, Minimum Essential 
Medium with  glutamine, trypsin/ethylenediamine tetra-acetic 
acid (EDTA) 1×  solution, fetal bovine serum, and penicillin-
streptomycin solution were obtained from Gibco (Invitrogen 
Corporation, Warrington, UK). Cytarabine was purchased 
from Sequoia Research (Pangbourne, UK). Pluronic F68 
was provided by BASF (Cesano Maderno, Italy). All other 
materials and solvents used in this investigation were of 
analytical grade (Carlo Erba, Milan, Italy).
Synthesis and characterization  
of Sq-Ara-C
1H nuclear magnetic resonance (NMR) spectra were recorded 
on a Bruker 300 ultrashield instrument (Karlsruhe,  Germany) 
for samples in CDCl
3
 solution at room temperature, with 
Me
4
Si as the internal standard. Coupling constants (J) are 
expressed in Hz. Mass spectra were recorded on a Finnigan 
MAT TSQ 700 spectrometer (San Jose, CA). The  reactions 
were monitored by thin layer chromatography on  precoated 
F
254
 silica gel sheets (Merck, Darmstadt, Germany); 
after being developed, the sheets were exposed to iodine 
vapor. Flash-column chromatography was performed on 
230–400 mesh silica gel. Tetrahydrofuran was dried over 
sodium benzophenone ketyl. All solvents were distilled prior 
to flash chromatography.
The synthesis of 1,1′,2-tris-nor-squalene acid  (compound 2) 
is reported in Scheme 1. 1,1′,2-tris-nor-squalene aldehyde 1 
(1.58 g, 4.12 mmol) was dissolved in 20 mL of diethyl ether 
at 0°C. Sulfuric acid (2.3 mL) was separately added at 0°C 
to 20 mL of distilled water with stirring, followed by potas-
sium dichromate (1.21 g, 4.12 mmol), to obtain chromic acid. 
It was then added to the solution of aldehyde 1 (which had 
been previously prepared) at 0°C over a period of 20 minutes, 
and left to react for 2 hours at 0°C with stirring. The reaction 
mixture was extracted with diethyl ether (50 mL × 3), washed 
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Scheme 1 Synthesis of 4-(N)-1,1′,2-tris-nor-squalenoyl-cytarabine (Sq-Ara-C, compound 3) starting from 1,1′,2-tris-nor-squalene aldehyde (compound 1), which was first 
oxidized into 1,1′,2-tris-nor-squalene acid (compound 2) and then conjugated with Ara-C.
with saturated brine, dried over anhydrous sodium sulfate, and 
evaporated in vacuo. Completion of the reaction was confirmed 
by silica gel thin layer chromatography, which was developed 
with light petroleum/diethyl ether/methanol (70:23:7 v/v/v). 
The crude product was purified by flash chromatography with 
light petroleum, then light petroleum/diethyl ether (95:5 v/v) 
as the eluent, to yield 578 mg of 1,1′,2-tris-nor-squalene acid 2 
(35% yield), as a colorless oil. 1H NMR (CDCl
3
): δ, 1.55–1.63 
(m, 18 H, allylic CH
3
), 1.90–2.05 (m, 16 H, allylic CH
2
), 
2.26 (t, 2 H, CH
2
CH
2
COOH), 2.38 (t, 2 H, CH
2
CH
2
COOH), 
5.00–5.19 (m, 5 H, vinylic CH), 12.20 (broad, 1 H, COOH). 
MS (EI): m/z 400 (M+, 5), 357 (3), 331 (5), 289 (3), 208 (6), 
136 (3), 81 (100).
The synthesis of 4-[(N)-1,1′,2-tris-nor-squalenoyl]-1β-
(arabinofuranosyl)-cytosine (Sq-Ara-C, compound 3) was 
carried out as reported in Scheme 1. Compound 2 (338 mg, 
0.845 mmol) was dissolved in 5 mL of anhydrous tetrahy-
drofuran in a three-necked flask under nitrogen with stirring, 
followed by addition of triethylamine (85.5 mg, 0.845 mmol) 
in 2 mL of anhydrous tetrahydrofuran, with cooling to 0°C. 
Ethyl chloroformate (91.7 mg, 0.845 mmol) dissolved in 
82 mL of anhydrous tetrahydrofuran was then added and left 
at 0°C for 20 minutes, with stirring, followed by addition of 
Ara-C (205.52 mg, 0.845 mmol) dissolved in 5 mL of warm 
anhydrous dimethylformamide, due to its scarce solubility. 
After reaching room temperature, the mixture was allowed 
to react for 3 days, with stirring under nitrogen. The reaction 
mixture was then controlled by silica gel thin layer chroma-
tography, which was developed with light dichloromethane/
acetone (95:5 v/v). The crude product was purified by 
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flash chromatography with dichloromethane, then dichlo-
romethane/acetone (85:15 v/v), and finally dichloromethane/
acetone (75:25 v/v) as mobile phases, to give 296 mg of 
Sq-Ara-C (compound 3, scheme 1, 56% yield), as a colorless, 
viscous oil.22 1H-NMR (CD
3
COCD
3
): δ, 1,55–1,68 (18 H, m, 
allylic CH
3
), 1,97–2,12 (16 H, m, allylic CH
2
), 2,35 (2 H, t, 
NHCOCH
2
CH
2
), 2,64 (2 H, t, NHCOCH
2
), 3,88 (2 H, m, 
5′-CH
2
), 4,08 (1 H, m, 4′-CH), 4,24–4,30 (2 H, m, 2′-CH 
and 3′-CH), 4.65–5.00 (3 H, broad peaks, OH), 5,02–5,25 
(5 H, m, vinylic CH), 6,189 and 6.200 (1 H, d, J = 3.0 Hz, 
1′-CH), 7,323 and 7.349 (1 H, d, J = 9.0 Hz, 5-CH), 8,187 
and 8.212 (1 H, d, J = 9.0 Hz, 6-CH), 9.58–9.68 (1 H, broad 
peak, NHCO). 1H-NMR (CD
3
OD): δ, 1,55–1,68 (18 H, m, 
allylic CH
3
), 1,97–2,12 (16 H, m, allylic CH
2
), 2,35 (2 H, t, 
NHCOCH
2
CH
2
), 2,54 (2 H, t, NHCOCH
2
), 3,90 (2 H, m, 
5′-CH
2
), 4,03 (1 H, m, 4′-CH), 4,10 (1 H, m, 3′-CH), 4,250 
(1 H, m, 2′-CH), 5,02–5,25 (5 H, m, vinylic CH), 6,192 and 
6.205 (1 H, d, J = 3.9 Hz, 1′-CH), 7,424 and 7.449 (1 H, d, 
J = 7.5 Hz, 5-CH), 8,230 and 8.255 (1 H, d, J = 7.5 Hz, 
6-CH). MS (CI): m/z 627 (M+, 100), 609 (65).
Preparation and characterization  
of Sq-Ara-C nanoassemblies
Sq-Ara-C nanoparticles were prepared using the nanopre-
cipitation method. Briefly, Sq-Ara-C was dissolved in ace-
tone 10 mg/mL and added to an aqueous dextrose solution 
(5% w/v) drop by drop, under stirring at 500 rpm in such a 
way as to promote self-assembly of the nanoparticles. The 
acetone used in this procedure was completely evaporated 
using a R210 rotary evaporator (Büchi-Italia, Milan, Italy), 
thus providing quantitative assembling of Sq-Ara-C. Pure 
squalene nanoparticles were obtained by nanoprecipitation 
of an ethanolic solution of squalene in an aqueous dextrose 
solution (5% w/v) containing Pluronic F68 (1% w/v).
The morphology of the Sq-Ara-C nanosystems was 
evaluated using a transmission electron microscope (Philips, 
Eindhoven, The Netherlands). Samples were analyzed at 
100 kV. A drop of the sample was deposited on a copper 
screen coated with carbon. The sample was dried and then 
contrasted with uranyl acetate for 2 minutes and then washed 
with distilled water.
The mean size and polydispersity index of the Sq-Ara-C 
nanosystems were evaluated by dynamic light scattering. 
Dimensional analysis was carried out by photocorrelation 
spectroscopy (Nanosizer Nano ZS, Malvern Instruments 
Ltd, Worcestershire, UK) using a 4.5 mW laser operating at 
670 nm. Experiments were carried out at a back-scattering 
angle of 173°. Samples were suitably diluted with Milli-Q® 
water (Millipore Corporation, Billerica, MA) to avoid 
multiscattering phenomena and placed in a quartz cuvette. 
Experiments were carried out at room temperature. For each 
sample, 30 different measurements were performed.
Fluorescein-DHPE (0.1% molar) was used to prepare 
fluorescent-labeled Sq-Ara-C nanosystems by  dissolving 
the probe in the organic phase during the preparation 
process.
The Zetasizer Nano ZS was also used for zeta potential 
determination by applying a Smoluchowski constant F (Ka) 
of 1.5 to calculate the zeta potential value as a function 
of the electrophoretic mobility of the nanosystem. The 
various measurements were carried out in triplicate on 
three different batches (10 determinations for each batch). 
Results were expressed as the mean of three different 
experiments ± standard deviation.
Cell cultures
L1210 (murine leukemia) and K562 (human chronic 
myelogenous leukemia) cells were incubated (Guaire® TS 
Autoflow Codue water-jacketed incubator) in plastic cul-
ture dishes (100 mm × 20 mm) at 37°C (5% CO
2
) using 
RPMI 1640 medium with glutamate, penicillin 100 IU/mL, 
streptomycin 100 µg/mL, and fetal bovine serum 10% v/v. 
The culture medium used for the MCF-7 (estrogen-responsive 
human breast cancer) cells was Minimum Essential Medium 
supplemented with glutamine, D-glucose, pyruvate, 
10% (v/v) fetal bovine serum, penicillin 100 IU/mL, and 
streptomycin 100 µg/mL. The medium was replaced with 
fresh medium every 48 hours. When about 80% confluence 
was reached, the cells were treated with trypsin (in the 
case of adherent cells) to separate them from the dishes 
and  collected into a centrifuge tube containing 4 mL of the 
 culture medium. The dishes were washed again with 2 mL of 
phosphate-buffered saline to remove the remaining cells, and 
then the phosphate-buffered saline was transferred into the 
centrifuge tube. The tube was centrifuged at 1000 rpm and 
room temperature for 10 minutes using a Heraeus Sepatech 
Megafuge 1.0. The pellet was resuspended in an appropriate 
culture medium volume and seeded in culture dishes before 
investigation in vitro.
Induction of resistance to Ara-C  
in L1210 cells
Resistance to Ara-C was induced by a graduated increase in 
drug concentration in the culture medium. The drug concen-
trations used were 0.001 (for 7 days), 0.05 (for 7 days), 0.25 
(for 10 days), 0.50 (for 15 days), and 1.00 µM (for 15 days), 
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in that order. Cells were considered to be resistant to Ara-C 
(L1210R cells) when proliferation was undisturbed in the 
presence of a drug concentration of 1 µM.25
Evaluation of in vitro cytotoxic activity
The cytotoxic effects of Ara-C and the Sq-Ara-C nanomedi-
cine were evaluated using the MTT test for cell viability. The 
cultured cells were plated in 96-well culture dishes (5 × 103 
cells/0.2 mL for MCF-7 cells and 8 × 103 cells/0.2 mL 
for K562, L1210, and L1210R cells) and incubated for 
24 hours at 37°C to promote their adhesion/settling onto the 
plate. The culture medium was then removed, replaced with 
the different formulations at different drug concentrations, 
and incubated for 24 and 48 hours. Each plate had eight 
wells containing untreated cells as the control and eight 
wells containing cells treated with pure squalenoyl nano-
systems (without Ara-C) as the blank. After each incubation 
period, 10 µL of tetrazolium salt solubilized in phosphate-
buffered solution (5 mg/mL) were added to each well and 
the plates were then incubated again for 3 hours. After this 
period, the plates containing K562 and L1210 cells were 
centrifuged at 1500 rpm for 5 minutes (ALC PK130) in 
order to obtain deposition of salts on the bottoms of the 
wells. The medium was removed and the formazan salts 
(precipitated on the well bottom after oxidation) were dis-
solved with 200 µL of a mixture of dimethyl sulfoxide/
ethanol (1:1 v/v) by shaking the plates for 20 minutes 
at 230 rpm (IKA® KS 130 Control, IKA® Werke GmbH 
and Co, Staufen,  Germany). The solubilized formazan 
was quantif ied using a microplate spectrophotometer 
(Multiskan MS 6.0,  Labsystems, Kilsyth, Australia) at a 
wavelength of 540 nm with reference at a wavelength of 
690 nm. The percentage of cell viability was calculated 
according to the following equation:
 Cell viability (%) = AbsT/AbsC × 100 (1)
where AbsT is the absorbance of treated cells and AbsC 
is the absorbance of control (untreated) cells. The forma-
zan concentration is directly proportional to cell viability, 
which was reported as the mean of five different experi-
ments ± standard deviation.
Interaction of Sq-Ara-C  
nanomedicine with cells
The rate of interaction between the Sq-Ara-C nanomedicine 
and the different cell lines (L1210, L1210R, K562, and 
MCF-7) as a function of time (0.5, 1, 2, 4, 6, and 12 hours) 
was investigated. [3H]CHE-radiolabeled (0.003% w/w 
 corresponding to 3 nmol of [3H]CHE) nanosystems were 
used. All nanosystems were centrifuged (80,000 × g for 
30 minutes at 4°C) and resuspended in a suitable medium 
before each investigation in order to prevent interference 
related to the [3H]CHE molecules that were not integrated 
into the nanoaggregates. In particular, cells were plated in 
six-well culture dishes (5 × 105 cells/mL) and successively 
treated with 100 µL of tritiated formulation. After different 
incubation times, the cells were centrifuged (1200 rpm at room 
temperature for 10 minutes) to eliminate the culture medium, 
washed twice with phosphate-buffered saline, transferred 
into polypropylene liquid scintillation vials (20 mL size) 
(Sigma-Aldrich Chemie, GmbH, Steinheim, Germany), and 
dissolved in 2 mL of a quaternary ammonium hydroxide 
solution (BTS-450, Beckman Instruments Inc, Fullerton, 
CA) under continuous shaking for one hour at 60°C using an 
incubator shaker (Innova 4300, New Brunswick Scientific, 
Edison, NJ). At the end of the incubation period, 7 mL of 
liquid scintillation cocktail (Ready Organic, Beckman Coulter 
Inc, Fullerton, CA) were added, the samples were vigorously 
mixed and analyzed using a Wallac Win Spectral 1414 
 liquid scintillation counter (PerkinElmer Life and Analytical 
 Sciences Inc, Waltham, MA). A 1414 Win Spectral Wallac 
LCS software program was used for data analysis.
Confocal laser scanning microscopy
Interaction between breast cancer cells and the fluorescein-
labeled Sq-Ara-C nanomedicine was evaluated by confocal 
laser scanning microscopy studies. For these experiments, 
4 × 105 cells/mL were placed in six-well culture plates with 
culture medium, and a sterile glass slide was positioned onto 
each well. Plates were incubated for 24 hours and the cells 
were then treated with fluoresceinated nanosystems for differ-
ent incubation times. After incubation, each well was washed 
three times with phosphate-buffered saline to remove excess 
Sq-Ara-C, and the cells were then fixed on sterile glass slides 
using 1 mL of ethanol solution (70% v/v). Each slide was 
washed three further times with phosphate-buffered saline, 
and 2 mL of phosphate-buffered saline was added to each 
well. Plates were stored at 4°C up to the time of the confocal 
laser scanning microscopy analysis. Before analysis, cover 
slides were positioned over the glass slides using a glycerol 
solution (70% v/v) to remove any entrapped air, and they were 
then fixed with transparent glue. The analysis was carried out 
using a Leica TCS SP2 MP confocal laser scanning micro-
scope at λ
exc
 = 496 nm and λ
em
 = 519 nm. Scan resolution up 
to 4096 × 4096 pixels with an Ar/Kr laser beam of 75 mW, 
equipped with a fluorescein analyzer filter, was used for the 
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experimental investigations. Samples were recorded using a 
macrodeveloper software package having multidimensional 
series acquisition and direct-access digital control knobs. An 
immersion oil lens 100× was used.
In vivo experiments
The animal experiments were carried out in agreement with the 
principles and procedures outlined by the local ethics  committee 
and in accordance with the European Communities Council 
Directive of November 24, 1986 (86/609/EEC). The animals 
were maintained under standard conditions of both temperature 
(20°C ± 2°C) and humidity (65%) on a 12-hour light/12-hour 
dark cycle (light on 8 am), with food and water ad libitum.
In vivo antitumoral activity
Four-week-old DBA/2 mice weighing about 20–25 g (Harlan, 
San Pietro al Natisone, Udine, Italy) were used for the study. 
L1210R cells were maintained in vitro and injected intra-
venously (1 × 105 cells/100 µL phosphate-buffered saline) 
into the mice, to obtain an aggressive metastatic leukemia 
model. The mice were then divided into five groups of ten 
animals each and treated on days 4, 8, 12, 16, and 20 with the 
 following formulations: saline solution (NaCl 0.9% w/v) as a 
control, Ara-C 100 mg/kg, Sq-Ara-C nanomedicine (50 mg/kg 
equivalent of Ara-C), pure squalene nanosystems (drug absent), 
and a physical mixture of squalene nanosystems and Ara-C 
100 mg/kg. The body weight, feeding behavior, and motor 
activity of the mice were used as indicators of general health.
Biodistribution of Sq-Ara-C 
nanomedicine
Biodistribution experiments were also carried out using 
DBA/2 mice. [3H]CHE (0.003% w/w corresponding to 
3 nmol of [3H]CHE) radiolabeled nanosystems (200 µL) 
were injected into the mice through the tail vein.26 At different 
times, mice (three per time point) were sacrificed by cervical 
dislocation, and their hearts, lungs, livers, spleens, kidneys, 
and blood were collected. The organs were transferred in 
their entirety into 20 mL polypropylene liquid scintillation 
vials and mixed with 2 mL of a quaternary ammonium 
hydroxide solution under continuous shaking for 4 hours 
at 60°C to allow complete dissolution. At the end of the 
incubation period, various samples were decolorized with 
2 mL of 24% (v/v) H
2
O
2
 at room temperature for 5 minutes, 
and 7 mL of liquid scintillation cocktail were added. These 
mixtures were mixed vigorously and analyzed as described 
above. The 1414 Win Spectral Wallac LCS software was used 
for data analysis. To eliminate the radioactivity contained in 
the various organ samples and emanating from the nanosys-
tems contained in the vascular space and tissue parenchyma 
(including macrophages and capillary endothelial cells, 
X
tissue
), a correction was made according to the following 
equation:
 X
tissue
 = X
organ
 - (V
0
 × C
(t)
) (2)
where, X
organ
 represents levels of radioactivity recovered 
from the various organ samples; V
0
 is the total volume of 
the vascular space and interstitial fluid, as determined by the 
radioactivity level in various whole organ samples divided by 
blood concentration 10 minutes after intravenous injection of 
[3H]CHE-radiolabeled Sq-Ara-C nanomedicine; C
(t)
 is blood 
concentration at the indicated time. A further quenching cor-
rection factor was obtained by measuring the radioactivity 
of blank tissues from noninjected mice spiked with known 
amounts of [3H]CHE (0.030 µCu/µmol lipids).27
Pharmacokinetic experiments
DBA/2 mice were also used for the pharmacokinetic studies. 
Ara-C or Sq-Ara-C nanomedicine (1 mg/kg) was injected 
(100 µL) through the tail vein (groups of three animals per 
each time point). Blood samples (200 µL) were taken from the 
retro-orbital plexus and frozen. Immediately before analysis, 
the samples were defrosted and centrifuged (14,300 × g, 
10 minutes) at room temperature, and 50 µL of glacial ace-
tic acid was then added to the plasma samples to decrease 
the hydrogen bonding between nucleosides and proteins. 
Acetonitrile (1 mL) of high-pressure liquid chromatography 
grade (HPLC) was added to the plasma samples, which were 
then vortex-mixed and centrifuged at 800 × g for 15 minutes 
at 4°C. The supernatant was removed and collected in a 
glass tube, and 1 mL of acetonitrile was added to the pellet. 
Three cycles of vortex-mixing and centrifugation were car-
ried out. Supernatants were combined, evaporated to dryness 
under a nitrogen flux at 42°C (thermostated water bath), and 
stored at -20°C. Before the HPLC analysis, the residue was 
resuspended in 1 mL of water/methanol (55:45 v/v 1, HPLC 
grade), incubated for 5 minutes at 37°C, and then centri-
fuged at 12,000 × g for 10 minutes at 20°C. The supernatant 
was removed, filtered through a 0.22 µM pore size Anotop 
10 syringe filter  (Whatman, Springfield Mill, UK) and placed 
in 4 mL HPLC glass vials for analytical determination. 
Analysis was carried out using an HPLC system (Varian Inc, 
Palo Alto, CA) composed of a 200-2031 Metachem online 
degasser, a M210 binary pump, a ProStar 410 autosampler, 
a G1316A thermostated column compartment, and a 25 µL 
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CSL20 Cheminert sample loop injector. Data were acquired 
and processed with Galaxie® chromatography manager 
 software (Varian Inc). Chromatographic separation was carried 
out at room temperature using a GraceSmart RP C18 column 
(4.6 × 250 mm, 5 µM particle size, Alltech Grom GmbH, 
Rottenburg-Hailfingen, Germany). The mobile phase was 
water (pH 4.5)/methanol (55:45 v/v), pumped at a flow rate of 
1 mL per minute. Ultraviolet detection was set at 260 nm.
No interference coming from plasma components was 
observed for cytarabine and its HPLC metabolite (Ara-U) 
peaks. The chromatographic method provided suitable sepa-
ration of the peaks of cytarabine and Ara-U, which showed a 
retention time of 4.50 minutes and 6.0 minutes, respectively. 
Quantification of cytarabine was carried out using an external 
standard curve in the linear concentration range of 0.1 µg/mL 
to 20 µg/mL. A standard 1 mg/mL solution of cytarabine was 
used for construction of the standard curve. Plasma amounts 
of drug were determined using the standard curve according 
to the following equation:
 AUC = 0.76182 x + 0.1 (3)
where x is the drug concentration (µg/mL) and AUC is the 
area under the curve (mAu × minutes). Pharmacokinetic 
calculations were carried out using WinNonlin Professional, 
version 5.3 (Tharsight, Mountain View, CA). Plasma Ara-C 
levels were expressed as µg/mL. Experimental data are the 
mean of three different experiments.
Statistical analysis
All data are expressed as the mean ± standard deviation. 
Differences between the various experimental points were 
evaluated using one-way analysis of variance followed by 
the Tukey-Kramer multiple comparison test with GrafPAD 
Software for Science (San Diego, CA).
Results
Characterization of Sq-Ara-C 
nanoassemblies
Dynamic light scattering and transmission electron micro-
scopic analysis of the nanosystems showed a mean size of 
about 150 nm, with a polydispersity index of approximately 0.1 
(highly homogenous size distribution, Table 1, Figure 1A). 
Moreover, a surface charge of about -25 mV was obtained, 
confirming the results of previous investigations.20 These 
values represent ideal parameters able to assure ideal biophar-
maceutical properties for the nanoaggregates; in fact, various 
studies have demonstrated that the mean size and surface 
charge can influence biodistribution of a colloidal formulation 
after intravenous administration. In particular, a mean size of 
less than 200 nm allows a long circulation time.11
Evaluation of cytotoxicity in vitro
The antitumoral efficacy of the Ara-C and Sq-Ara-C nano-
medicine was evaluated in the different cancer cell lines in 
order to investigate whether the colloidal formulation was 
able to improve the antitumoral activity of the nucleoside 
analog. In particular, we used a leukemic murine cell line 
(L1210) which is very responsive to Ara-C, a resistant analog 
line (L1210R), a human leukemia cell line (K562), and a 
human breast cancer cell line (MCF-7). Squalenoyl nanosys-
tems containing no drug did not decrease cell viability at the 
same dosages as used for Sq-Ara-C. The Sq-Ara-C nanomed-
icine improved the antitumoral effect of the active compound 
in all the cell lines investigated. As shown in Table 2, after 
24 hours of incubation, Sq-Ara-C allowed reduction of the 
drug dosage by approximately 2.0-fold in L1210 cells, about 
1.5-fold in L1210R, cells and about 2.5-fold in K562 cells in 
comparison with Ara-C. It was very interesting to observe 
that squalenoylation enabled Ara-C to exert its cytotoxic 
effects even on the MCF-7 cell line, which is generally less 
responsive to chemotherapy. In fact, Sq-Ara-C nanomedicine 
reduced cell viability by 50% at a dose of about 55 µM while 
Ara-C achieved the same reduction at a concentration greater 
than 100 µM. After 48 hours of incubation, the difference in 
IC
50
 between the two formulations became more evident in 
the different cancer cell lines. The Sq-Ara-C nanomedicine 
achieved a further reduction in IC
50
 of about 2.5-fold in 
L1210R cells and about 4.0-fold in K562 and MCF-7 cells 
with respect to Ara-C. The cytotoxic effect was similar only 
in the L1210 cells, probably as a consequence of their great 
sensitivity to the active compound.
Interaction between Sq-Ara-C 
nanomedicine and cell lines
The improved cytotoxic effect of Ara-C conjugated with 
squalenic acid encased in a nanosystem could be due to greater 
Table 1 Physicochemical parameters of squalenoyl nano aggregates*
Samples Size (nm) Polydispersity 
index
Zeta  
potential
Squalenoyl  
nanoassemblies
105.6 ± 12.7 0.08 ± 0.019 -24.8 ± 5.6
Sq-Ara-C  
nanomedicine
146.1 ± 6.7 0.09 ± 0.015 -26.5 ± 3.1
Note: *Each value represents the average of three different experiments ± standard 
deviation.
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Figure 1 Transmission electron micrograph of the Sq-Ara-C nanoaggregates (A). Interaction between [3H]CHE radiolabeled Sq-Ara-C and the different cancer cell lines (B). 
Confocal laser scanning micrograph (C), relative three-dimensional image (D) and 4× zoom (E) showing the interaction between MCF-7 cells and the fluorescein-DHPE-
labeled Sq-Ara-C nanoaggregates after 3 hours of incubation.
intracellular localization of the drug, so an investigation of 
the cell-nanosystem interaction using [3H]CHE- radiolabeled 
Sq-Ara-C nanomedicine was carried out. As shown in 
Figure 1B, after 4 hours of incubation, peak interaction 
between the Sq-Ara-C nanomedicine and the leukemic cell 
lines (K562, L1210, and L1210R) was reached, while the 
greatest intracellular colloidal accumulation in MCF-7 cells 
was reached after 12 hours (Figure 1B).
Data on the interaction between [3H]CHE-radiolabeled 
Sq-Ara-C nanomedicine and MCF-7 cells were in very 
good agreement with the findings of confocal laser scanning 
microscopy. Namely, after only 3 hours of incubation, the 
fluorescein-labeled Sq-Ara-C nanomedicine interacted strongly 
with the MCF-7 cells, giving them a characteristic green color 
(Figure 1C–E). It is interesting to note the presence of fluores-
cent spots on the cell membrane (Figure 1D), probably as a 
consequence of colloidal adsorption/fusion with the cells.28
In vivo antileukemic activity  
of Sq-Ara-C nanomedicine
The in vivo anticancer activity of the Sq-Ara-C nanomedicine 
(50 mg/kg) with respect to a simple solution of Ara-C at a 2.0-
fold higher drug dosage was evaluated in L1210R leukemia-
bearing mice. A colloidal formulation of pure squalenoyl 
nanosystems was used as the blank. Weight loss, dehydration, 
and limb paralysis were considered characteristic symptoms 
of leukemic pathology. The untreated control mice and ani-
mals treated with the blank developed these symptoms 6 days 
after injection of leukemic cells. Treating the mice with the 
different drug formulations caused delayed appearance of 
the aforementioned symptoms (Table 3).
As mentioned, weight loss is a clear sign of leukemia and 
is related directly to the severity of the disease, ie, the greater 
Table 2 Evaluation of IC50 (µM) of Ara-C and Sq-Ara-C in different 
cancer cell lines*
24 hours 48 hours
Ara-C Sq-Ara-C Ara-C Sq-Ara-C
L1210 0.051 ± 0.012 0.027 ± 0.008 0.022 ± 0.003 0.017 ± 0.006
L1210R 71.7 ± 3.8 44.6 ± 2.6 48.2 ± 5.3 19.0 ± 4.9
K562 55.9 ± 4.9 21.8 ± 6.0 19.6 ± 2.3 4.2 ± 1.5
MCF-7 .100 56.3 ± 5.8 .100 28.0 ± 2.9
Note: *Each value represents the average of five different experiments ± standard 
deviation.
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survival, demonstrating that the active compound has to be 
covalently linked to squalenic acid in order to improve its 
antileukemic efficacy.
Biodistribution and pharmacokinetic 
profile of Sq-Ara-C nanomedicine
Evaluation of the biodistribution profile of the [3H]CHE-
radiolabeled Sq-Ara-C nanomedicine showed localization 
of the nanosystems in various organs following intravenous 
administration to DBA/2 mice. As shown in Figure 3, after 
one hour, many of the nanosystems were localized in the 
spleen, liver, and lungs as a consequence of uptake by 
macrophages in the reticuloendothelial system, while the 
colloids concentrated to a lesser degree in other organs. After 
the same period of time, a large amount of the administered 
dose was detected in the bloodstream. Localization of 
[3H]CHE-radiolabeled  Sq-Ara-C nanomedicine in the organs 
of the reticuloendothelial system was progressive, and after 
24 hours was found to be particularly concentrated in the 
spleen, while the amount present in the bloodstream was 
 substantially reduced. On the other hand, the presence of 
about 8% of the injected dose in the blood compartment 
indicated that conjugation of the active compound with a 
squalenic acid chain could be the cause of the increase in 
plasma half-life of the nucleoside analog after 24 hours, thus 
augmenting its antitumoral efficacy. Moreover, no appreciable 
difference (data not reported) in the biodistribution profiles 
was observed between the Sq-Ara-C nanomedicine and the 
squalenoyl nanosystems, showing that biodistribution was 
Table 3 Evaluation of physiological parameters in mice treated 
with the different formulations
Samples Elapsed  
time1 (days)
Mean weight  
loss2 (g)
50% survival3 
(days)
Control 6 ∼3.2 24
Pure Sq-Na 6 ∼2.6 22
Ara-C (100 mg/kg) 14 ∼1.4 38
Physical mixture  
Ara-C/pure Sq-Na
15 ∼1.0 39
Sq-Ara-C (50 mg/kg) 46 ∼0.4 70
Note: 1Time of appearance of symptoms of leukemia; 2weight loss in mice not 
inoculated with L1210R cells; 3days elapsed resulting in death of 50% of mice.
the weight loss the more severe the leukemic pathology. 
Treatment of mice with the various Ara-C formulations 
resulted in a weight reduction with respect to the untreated 
animals in the following decreasing order: Sq-Ara-C nano-
medicine 50 mg/kg . Ara-C 100 mg/kg and a physical 
mixture of Ara-C/squalenoyl nanosystems . squalenoyl 
nanosystems. The increased antileukemic effectiveness 
of the Sq-Ara-C nanomedicine was confirmed further by 
evaluating survival of leukemic-bearing mice as a function 
of time. As shown by the data on the survival rates for mice 
treated with the different formulations reported in Figure 2, 
the control group showed the same survival profile as mice 
treated with the squalenoyl nanosystems, while the Sq-Ara-C 
nanomedicine provided the greatest antileukemic effect. The 
Ara-C and the physical mixture of Ara-C/squalenoyl nano-
systems induced the same variation in percentage of mouse 
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Figure 2 Survival profile of mice inoculated intravenously with 1 × 105 L1210R cells 
and treated with the different formulations.
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Figure 3 Biodistribution of [3H]CHE radiolabeled Sq-Ara-C nanoaggregates in 
DBA/2 mice as a function of time.
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innovative nanosystems with a mean size of about 150 nm. 
The nanoaggregates were observed to enable suppression of 
resistance of L1210R cells (which possess a downregulated 
dCK gene)25 to the drug compound. In addition, the nanoag-
gregates favored a decrease in the IC
50
 of wild-type L1210 
and K562 cells. A possible explanation is related to the deami-
nation process necessary to degrade nucleosides. In the case 
of nanoaggregates, the presence of the amide linkage makes 
the colloids resistant to the enzymatic action of intracellular 
deaminases. It has also been shown that leukemic cells are 
rich in cathepsin B (a cysteine protease), which induces rapid 
cleavage of the Sq-Ara-C nanomedicine, releasing the active 
compound and allowing it to exert its antitumoral activity.31 It 
is interesting to note that the nanoaggregates had a stronger 
cytotoxic effect with respect to the free form, although the 
breast cancer cell line was less responsive to cytarabine than 
were the other experimental cell lines, which caused accu-
mulation of a greater amount of the nanomedicine.
It is probable that the improved in vitro anticancer effect 
of the Sq-Ara-C nanomedicine with respect to Ara-C is 
related to: resistance of the nanoaggregates to the action 
of intracellular deaminases; the large concentration of 
cathepsin B inside the tumoral cells; and the capacity of the 
active compound to penetrate tumor cells without the help 
of membrane nucleoside transporters, although the exact 
mechanism for this is not fully understood and is currently 
under investigation.28,32
The in vivo leukemic model confirmed our in vitro results, 
showing that the Sq-Ara-C nanomedicine achieves a better 
survival rate in treated mice than in those treated only with 
Ara-C. This finding is consistent with the results obtained 
with squalenoyl-gemcitabine in a leukemic murine model, 
validating the efficacy of squalenoylation as an innovative 
approach to the synthesis of nanomedicines.20,33 In addition, it 
was interesting to note that [3H]CHE-radiolabeled Sq-Ara-C 
nanomedicine concentrated in the liver and spleen, which, 
apart from bone marrow, are the major organs involved in 
metastatic lymphocytic leukemia.34 This trend was due to 
the phagocytic action of the reticuloendothelial system, 
which is able to recognize colloids. However, uptake of Sq-
Ara-C nanomedicine by the reticuloendothelial system was 
gradual, as seen in the pharmacokinetic data, which meant 
that Sq-Ara-C nanomedicine was detectable in the blood-
stream for more than 24 hours following administration. 
Although the circulatory system is rich in deaminases other 
than just cytidine deaminase, it was demonstrated that 
squalene could interact with very low-density lipoproteins, 
thereby delaying deamination of the active compound.29,35
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Figure 4 Pharmacokinetic profiles for free Ara-C and Sq-Ara-C in DBA/2 mice 
following intravenous administration of a 1 mg/kg dose. 
Note: Data are the mean of three independent experiments ± standard deviation.
influenced mostly by the characteristics of the nanoparticles 
rather than those of the conjugated drug.
Evidence of the protective role played by the squalenic 
chain in the plasma metabolism of Sq-Ara-C and its improved 
biopharmaceutical features was determined by evaluating the 
pharmacokinetic profile of the Sq-Ara-C nanomedicine with 
respect to the Ara-C solution after intravenous administration. 
The Sq-Ara-C nanomedicine extended the drug half-life in 
plasma, which increased surprisingly by 6.0-fold in compari-
son with the native Ara-C (Figure 4). Moreover, free Ara-C 
was completely undetectable 12 hours after administration, 
while quantification of the active compound was possible in 
the nanomedicine even after 24 hours.
These results are in agreement with those obtained by 
Couvreur et al who incubated squalenoyl-gemcitabine in 
human plasma for 24 hours, obtaining 80% of unmodified 
product with respect to free drug, and are also consistent with 
the findings of Reddy et al who investigated the pharmacoki-
netic profile of the same compound in mice.20,29
Discussion
Cytarabine is a hydrophilic molecule used widely in the treat-
ment of leukemia. Unfortunately, numerous mechanisms of 
cellular resistance complicate the pharmacological efficacy 
of cytarabine.30 To overcome this problem, we have developed 
a new nanomedicine able to improve the antitumoral effects 
of cytarabine by conjugating it with squalenic acid, form-
ing an amide linkage, which was done in order to obtain 
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Conclusion
Squalenoylation represents a novel synthetic approach which 
is able to modulate the biopharmaceutical properties of bioac-
tive compounds. The results obtained by Couvreur et al for the 
nucleoside analog, gemcitabine, and those reported here for 
Ara-C, led us to question whether this technological approach 
was really a valid starting point in the development of novel 
nanomedicines to be used in clinical practice. Although the 
advantages for the drug are irrefutable, it is the opinion of 
the authors that the clinical application of squalenoyl nano-
medicine is not foreseeable in the near future, due to the 
fact that when a completely new compound is synthesized, 
a long road of regulatory procedures has to be embarked 
on to obtain approval for clinical use. However, further 
technological advancements ie, long circulation times and/
or selective targeting features, will enable the development 
of novel squalenoyl-based nanomedicines, the importance 
of which is hardly negligible in anticancer therapy.
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